Economic Impact of Biosynthesis on the Cannabis Industry - Seite 2
With capital intensive infrastructure investment, weather and facility risks, on-going operating costs and contamination possibilities, cannabis companies may soon rely on natural and chemical synthesis processes to extract valuable cannabinoid compounds for use in medicinals and potential new pharmaceutical drug development.
Meaningful economic impact on profits should easily accrue to cannabis companies capable of shedding all the costs and challenges associated with current cultivation to extraction methods. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) is scientifically bypassing the horticultural approach to cannabinoid production by developing a robust, high-yield biosynthesis process. The company's proprietary cannabinoid manufacturing process combines the inherent safety and known efficacy of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. InMed's innovative process targets significant cost savings as well as enhanced production, purification and quality control compared to existing grow-harvest-extract-purify methods employed by other companies. With similar scientific approaches used in multiple pharmaceutical applications, InMed's biosynthesis system will allow the extraction of all of the 90+ naturally occurring cannabinoids. InMed's proprietary biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids is a transformative technology in the rapidly emerging cannabinoid pharmaceutical, nutraceutical and medicinal sectors.
Using its exclusive process in a controlled laboratory setting, InMed's scientists can create cannabinoid compounds that are identical to those found in nature without the difficult, expensive and time-consuming challenges of planting, growing and harvesting cannabis then laboriously extracting the individual cannabinoids for medical use. It also completely eliminates any need for fertilizers or pesticides. To protect this valuable asset, InMed recently filed a provisional patent for biosynthesis of cannabinoids. Once converted into an International Patent Cooperation Treaty (PCT) application, InMed will aggressively pursue key international jurisdictions.
Aktuelle Themen
Weitere Artikel des Autors
2 im Artikel enthaltene WerteIm Artikel enthaltene Werte